Pharmena S.A. (PHR.WA)
PLN 4.0
(-3.15%)
PLN 4.0
(-3.15%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 28.94 Million PLN | 1890.9% |
| 2022 | -1.61 Million PLN | 65.16% |
| 2021 | -4.63 Million PLN | 33.33% |
| 2020 | -6.95 Million PLN | 27.32% |
| 2019 | -9.57 Million PLN | -2056.08% |
| 2018 | -444 Thousand PLN | 81.41% |
| 2017 | -2.38 Million PLN | -43.57% |
| 2016 | -1.66 Million PLN | 53.98% |
| 2015 | -3.61 Million PLN | 11.5% |
| 2014 | -4.08 Million PLN | -43.72% |
| 2013 | -2.84 Million PLN | 30.66% |
| 2012 | -4.1 Million PLN | -773.24% |
| 2011 | 608.99 Thousand PLN | 392.2% |
| 2010 | 123.73 Thousand PLN | -83.96% |
| 2009 | 771.54 Thousand PLN | 26.2% |
| 2008 | 611.36 Thousand PLN | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 235 Thousand PLN | 149.68% |
| 2024 Q2 | -904 Thousand PLN | -484.68% |
| 2023 Q1 | -147 Thousand PLN | 82.52% |
| 2023 Q3 | 30.13 Million PLN | 5387.54% |
| 2023 Q2 | -570 Thousand PLN | -287.76% |
| 2023 Q4 | -473 Thousand PLN | -101.57% |
| 2023 FY | 28.94 Million PLN | 1890.9% |
| 2022 Q3 | -119 Thousand PLN | 74.89% |
| 2022 Q2 | -474 Thousand PLN | -160.44% |
| 2022 Q4 | -841 Thousand PLN | -606.72% |
| 2022 FY | -1.61 Million PLN | 65.16% |
| 2022 Q1 | -182 Thousand PLN | 87.92% |
| 2021 Q2 | -1.92 Million PLN | -238.56% |
| 2021 FY | -4.63 Million PLN | 33.33% |
| 2021 Q4 | -1.5 Million PLN | -153.11% |
| 2021 Q3 | -595 Thousand PLN | 69.06% |
| 2021 Q1 | -568 Thousand PLN | 83.63% |
| 2020 Q1 | -757 Thousand PLN | 67.88% |
| 2020 Q2 | -1.59 Million PLN | -110.7% |
| 2020 Q4 | -3.46 Million PLN | -365.01% |
| 2020 FY | -6.95 Million PLN | 27.32% |
| 2020 Q3 | -746 Thousand PLN | 53.23% |
| 2019 Q2 | -5.44 Million PLN | -1001.21% |
| 2019 Q4 | -2.35 Million PLN | -106.94% |
| 2019 FY | -9.57 Million PLN | -2056.08% |
| 2019 Q1 | -494 Thousand PLN | 48.49% |
| 2019 Q3 | -1.13 Million PLN | 79.06% |
| 2018 Q3 | -3000.00 PLN | 97.78% |
| 2018 Q4 | -959 Thousand PLN | -31866.67% |
| 2018 FY | -444 Thousand PLN | 81.41% |
| 2018 Q2 | -135 Thousand PLN | -119.45% |
| 2018 Q1 | 694 Thousand PLN | 235.81% |
| 2017 FY | -2.38 Million PLN | -43.57% |
| 2017 Q2 | -933 Thousand PLN | -50.0% |
| 2017 Q1 | -622 Thousand PLN | -486.79% |
| 2017 Q3 | -323 Thousand PLN | 65.38% |
| 2017 Q4 | -511 Thousand PLN | -58.2% |
| 2016 Q3 | 33 Thousand PLN | 114.67% |
| 2016 FY | -1.66 Million PLN | 53.98% |
| 2016 Q4 | -106 Thousand PLN | -421.21% |
| 2016 Q2 | -225 Thousand PLN | 83.53% |
| 2016 Q1 | -1.36 Million PLN | 35.44% |
| 2015 Q1 | -688 Thousand PLN | 42.28% |
| 2015 Q3 | -88 Thousand PLN | 87.85% |
| 2015 Q4 | -2.11 Million PLN | -2304.55% |
| 2015 FY | -3.61 Million PLN | 11.5% |
| 2015 Q2 | -724 Thousand PLN | -5.23% |
| 2014 Q4 | -1.19 Million PLN | -360.23% |
| 2014 Q2 | -1.04 Million PLN | 34.07% |
| 2014 Q1 | -1.58 Million PLN | -38.69% |
| 2014 FY | -4.08 Million PLN | -43.72% |
| 2014 Q3 | -259 Thousand PLN | 75.26% |
| 2013 Q2 | -810 Thousand PLN | -70.17% |
| 2013 Q4 | -1.14 Million PLN | -177.91% |
| 2013 FY | -2.84 Million PLN | 30.66% |
| 2013 Q1 | -476 Thousand PLN | 66.0% |
| 2013 Q3 | -412 Thousand PLN | 49.14% |
| 2012 FY | -4.1 Million PLN | -773.24% |
| 2012 Q3 | -1.1 Million PLN | 0.0% |
| 2012 Q4 | -1.4 Million PLN | -26.47% |
| 2011 FY | 608.99 Thousand PLN | 392.2% |
| 2010 FY | 123.73 Thousand PLN | -83.96% |
| 2009 FY | 771.54 Thousand PLN | 26.2% |
| 2008 FY | 611.36 Thousand PLN | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Bioceltix S.A. | -13.68 Million PLN | 311.44% |
| BIOTON S.A. | 2.27 Million PLN | -1172.132% |
| Captor Therapeutics Spolka Akcyjna | -70.58 Million PLN | 141.002% |
| Mabion S.A. | 41.26 Million PLN | 29.872% |
| Molecure S.A. | -18.3 Million PLN | 258.077% |
| NanoGroup S.A. | -7.88 Million PLN | 466.814% |
| Poltreg S.A. | -13.55 Million PLN | 313.571% |
| Pure Biologics Spólka Akcyjna | -35.69 Million PLN | 181.081% |
| Ryvu Therapeutics S.A. | -92.11 Million PLN | 131.419% |
| Synthaverse S.A. | 4.75 Million PLN | -508.26% |
| Urteste S.A. | -5.58 Million PLN | 618.099% |